Fewer than one in 10 patients who could benefit from weight-loss injections like Wegovy have access to them, warns the World Health Organization as it publishes its first guidance on the therapies.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just access to this class of drugs.
Based on projections, more than two billion are projected to be living with obesity by 2030 without intervention.
"Our new guidance affirms that excess weight is a lifelong illness that can be addressed with thorough and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are key barriers to widespread availability to the jabs that can assist patients in reducing considerable body mass, explains the agency.
Weight-Loss Drug Scarcity
Even in the present most favorable case, the production of such drugs could only cover about 100 million people – under 10% of eligible patients, per the WHO.
The guideline urges governments and firms to increase access, by approaches like voluntary licensing.
A patent on a key compound – the core component of a leading brand – is set to lapse in several countries in 2026.
The Way Obesity Injections Work
These medications imitate a biological compound to delay gastric emptying, reduce hunger and increase feelings of fullness so individuals eat less.
People usually see weight reduction within a few weeks of commencing the once-weekly jabs.
Research suggests users may put most of the weight back on after a year of discontinuing the medication, as their typical hunger come back.
To be carrying excess weight elevates your risk for contracting diseases, like diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight impacts people in all nations and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
